Gland Pharma Limited has informed the Exchange about Investor Presentation
GLAND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Gland Pharma shared its Q4 and FY25 results via an investor presentation. Consolidated FY25 revenue was flat at ₹56,165 Mn, while PAT fell 10% YoY to ₹6,985 Mn (12% margin). Q4 FY25 revenue declined 7% YoY to ₹14,249 Mn with PAT down 3% at ₹1,865 Mn. The base business (Gland standalone) actually improved with FY25 EBITDA up 2% at ₹14,451 Mn (35% margin) and PAT up 4% at ₹10,868 Mn (26% margin). The drag came from subsidiary Cenexi, which posted a €19 Mn EBITDA loss for FY25 though it is guiding to turn positive by Q3 FY26. R&D spend rose to ₹1,922 Mn (4.7% of revenue), supporting 4 new launches in Q4 (31 cumulative in FY25) and 32 ANDA approvals in FY25 (371 cumulative, 318 approved). The Board has recommended a final dividend of ₹18 per share.
Mixed quarter for shareholders: standalone Gland business showed healthy margin expansion, but consolidated numbers were pulled down by Cenexi losses and softer US/RoW volumes. The GLP-1 capacity build-out (40M to 140M units), complex injectables pipeline ($6.5Bn TAM), and USFDA clean inspections are positive long-term signals, while the ₹18 dividend offers near-term shareholder return.